Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 5/20 | 0.74 |
| ▸ | MAOB | P27338 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.65 |
| ▸ | BCHE | P06276 | 2/20 | 0.65 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.65 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994069 | 1.00 | P4HB (0.74) | P4HBMAOBMAPTCYP1B1BCHE | |
| SCHEMBL30384014 | 1.00 | P4HB (0.74) | P4HBMAOBMAPTCYP1B1BCHE | |
| SCHEMBL7338947 | 0.95 | P4HB (0.77) | P4HBMAOBMAPTCYP1B1BCHE | |
| SCHEMBL31233485 | 0.95 | P4HB (0.77) | P4HBMAOBMAPTCYP1B1BCHE | |
| SCHEMBL7338954 | 0.95 | P4HB (0.77) | P4HBMAOBMAPTCYP1B1BCHE | |
| SCHEMBL11452322 | 0.92 | P4HB (0.78) | P4HBMAOBMAPTCYP1B1BCHE | |
| SCHEMBL30383950 | 0.92 | P4HB (0.78) | P4HBMAOBMAPTCYP1B1BCHE | |
| SCHEMBL11452324 | 0.92 | P4HB (0.78) | P4HBMAOBMAPTCYP1B1BCHE | |
| SCHEMBL2993136 | 0.91 | P4HB (0.82) | P4HBMAOBMAPTCYP1B1BCHE | |
| SCHEMBL2993138 | 0.91 | P4HB (0.82) | P4HBMAOBMAPTCYP1B1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-7787085-B2 | Optical alignment method and liquid crystal display element | JSR CORPORATION (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20080123046-A1 | OPTICAL ALIGNMENT METHOD AND LIQUID CRYSTAL DISPLAY ELEMENT | JSR CORPORATION (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20050259203-A1 | Optical alignment method and liquid crystal display element | JSR CORPORATION (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1353217-A1 | Optical alignment method and liquid crystal display element | JSR Corporation (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-6224788-B1 | AROMATIC UNSATURATED KETONE POLYMERS | JSR CORPORATION (JP) | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | P4HB 552/4885MAOB 1004/4885MAPT 3297/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | P4HB 469/4885MAOB 2435/4885MAPT 3512/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | P4HB 469/4885MAOB 2435/4885MAPT 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.